Mounjaro vs. Zepbound
Gleiches Tirzepatid — Unterschiedliche Zulassung & Kostenübernahme
Mounjaro und Zepbound sind dasselbe Medikament: Tirzepatid von Eli Lilly. Mounjaro ist für Typ-2-Diabetes zugelassen, Zepbound für Gewichtsmanagement. Dosierung und Wirkung sind identisch. Tracken Sie beides in Shotlee.
Mounjaro vs. Zepbound auf einen Blick
Mounjaro (Diabetes)
- →Zulassung: Typ-2-Diabetes Management
- →Dosisstufen: 2,5 mg bis 15 mg wöchentlich
- →Senkt HbA1c signifikant (−2,3%)
- →Wird oft Off-Label zur Gewichtsreduktion verschrieben
- →Krankenkasse: Übernahme bei T2D oft möglich
Zepbound (Gewichtsverlust)
- →Zulassung: Chronisches Gewichtsmanagement
- →Zusatz-Zulassung: Schlafapnoe (2024)
- →~21% Gewichtsverlust in Studien (SURMOUNT-1)
- →Identische Dosierung wie Mounjaro
- →Krankenkasse: In DE meist Selbstzahler-Leistung
Wichtige Zahlen
| Factor | Mounjaro | Zepbound |
|---|---|---|
| Active molecule | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA indication | Type 2 diabetes | Obesity + obstructive sleep apnea |
| Dose range | 2.5–15 mg weekly | 2.5–15 mg weekly |
| Dose escalation | Same 4-week steps | Same 4-week steps |
| Weight loss data | ~22% at 15 mg (SURMOUNT-4 T2D) | ~20.9% at 15 mg (SURMOUNT-1 obesity) |
| Sleep apnea approval | No | Yes (2024) |
| T2D insurance coverage | Usually covered | Usually not covered |
| Obesity insurance coverage | Off-label only | Covered if qualifying |
| Monthly cost (uninsured) | ~$1,000–1,200 | ~$1,000–1,200 (autoinjector); lower via Lilly vials |
SURMOUNT-1 (Jastreboff et al., NEJM 2022) for obesity data; SURPASS trials for T2D data. [1, 2]
Warum gibt es zwei Namen?
Zepbound 15 mg (SURMOUNT-1)
20.9%
Mean body weight loss at 72 weeks in SURMOUNT-1 (N=2539, adults with obesity, no T2D).
Mounjaro HbA1c (SURPASS-2)
−2.3%
Mean HbA1c reduction at 40 weeks with tirzepatide 15 mg in the SURPASS-2 T2D trial.
SURMOUNT-5 vs Wegovy
~47%
More relative weight loss with tirzepatide vs semaglutide in the 2025 SURMOUNT-5 direct head-to-head.
Choose Based on Your Goal
You have type 2 diabetes
Weight loss is the primary goal
Obstructive sleep apnea
Insurance covers T2D but not obesity
Cost for self-pay patients
Why Two Brand Names?
Pharmaceutical companies seek separate FDA approvals for different indications — even when the drug is identical. This allows them to market the product to different specialties (endocrinology vs obesity medicine), negotiate insurance coverage separately, and set different formulary positions. The pharmacology is completely unchanged.
Zepbound gained an additional approval in 2024 for obstructive sleep apnea — the first medication ever specifically approved for this condition — making it the more versatile option for patients with multiple weight-related conditions.
If you have type 2 diabetes, your doctor will typically prescribe Mounjaro for better insurance coverage. If your primary goal is weight loss or you have sleep apnea, Zepbound is the on-label choice. In practice, the drugs are interchangeable — the brand name determines coverage.
Track Either in Shotlee
Shotlee supports both Mounjaro and Zepbound with the full 2.5–15 mg dose escalation schedule, injection reminders, weight tracking, and side effect logs. Switching brands does not affect your history.
Mounjaro vs Zepbound: Häufig gestellte Fragen
Ja, der Wirkstoff Tirzepatid ist in beiden Produkten in identischer Konzentration enthalten.
Ja, viele Ärzte verschreiben es dafür, da Zepbound in einigen Märkten (wie Deutschland) noch nicht unter diesem Namen flächendeckend verfügbar ist.
Quellen
Mounjaro oder Zepbound in Shotlee tracken
Vollständige Verfolgung der Dosiseskalation von 2,5–15 mg, Injektionserinnerungen und Gewichtskurven. Kostenlos.
🚀 Shotlee kostenlos nutzen